- Research works
- 1 fractional, all time
- Citations
- 25 17.9 per fractional work
- Top-10% rate
- 15.9% record average 16.5%
- Open access
- 64% world 28%
Not ranked overall: Cytovac (Denmark) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
Which research topics does Cytovac (Denmark) publish most on?
By volume in 2022–2025: CAR-T cell therapy research, Phagocytosis and Immune Regulation, Immunotherapy and Immune Responses and Immune cells in cancer.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 CAR-T cell therapy research Oncology 0 works
- 2 Phagocytosis and Immune Regulation Immunology 0 works
- 3 Immunotherapy and Immune Responses Immunology 0 works
- 4 Immune cells in cancer Immunology 0 works
- 5 Histone Deacetylase Inhibitors Research Molecular Biology 0 works
- 6 Genomics and Chromatin Dynamics Molecular Biology 0 works
- 7 Epigenetics and DNA Methylation Molecular Biology 0 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
Other research institutions in Hørsholm
- DHI
- Chr. Hansen (Denmark)
- Danish Gas Technology Centre (Denmark)
- ALK-Abelló (Denmark)
- Bioneer (Denmark)
- Danish National Metrology Institute
- Gubra (Denmark)
- Lyngsø Marine (Denmark)
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.